Preview: Pain Therapeutics 2016

23 – 24 May 2016 | Holiday Inn Kensington Forum, London UK

SMi’s 16th annual Pain Therapeutics conference will hone in on the latest innovations and novel approaches to pain therapy and analgesic drugs as well as look at the practicalities of using animal models and translational biomarkers in pain research.

Aimed at an audience of senior specialists in neurology, CNS, clinical sciences and pharmacology, Pain Therapeutics 2016 will keep attendees at the forefront of scientific breakthroughs to adapt to the growing need towards minimising opioid dependency and new drug discovery.

Presentations from a selection of leading pharmaceutical companies currently developing novel analgesic treatments including Glenmark, Pfizer, GSK, Grunenthal and Nektar Pharmaceuticals, will provide delegates with an understanding on key topics such as drug development mechanisms, neuropathic pain, severe chronic pain, sodium channels, industry challenges, plus much more! An interactive panel discussion on medical incidents in experimental clinical trials will be just one of the highlights at the conference this spring.

Unrivalled Speaker Line-up Includes:

  • Andrea Houghton, Executive Director, MSD (Merck & Co Within The Usa)
  • Catherine Stehman-Breen, VP Clinical Sciences, Regeneron Pharmaceuitcals Inc
  • Chao Chen, Therapy Area Head, Glaxosmithkline
  • Thomas Christoph, Senior Director, Head Of Pain Pharmacology, Grunenthal GmbH
  • Richard Butt, Senior Director, Research Project Leader, Clinical Research, Pfizer
  • Shaloo Pandhi, Global Program Medical Director, Novartis
  • Neelima Khairatkar Joshi, Senior Vice President, Glenmark Pharmaceuticals
  • Stephen Doberstein, Senior Vice President & Chief Scientific Officer, Nektar Therapeutics
  • Geert Jan Groeneveld, Research Director Neurology & Pain, Centre for Human Drug Research
  • Steven Kamerling, Therapeutic Area Head For Pain, Inflammation And Oncology, Zoetis
  • Praveen Anand, Professor of Neurology, Imperial College London

Reasons to Attend:

  • Explore different strategies to minimise risk of opioid dependency
  • Discover Pfizer’s achievements for the past year on voltage gated sodium channels
  • Learn about Glenmark’s experience on pain drug discovery
  • Develop translational assays to support a small molecule Nav1.7 inhibitor programme

Further information and full speaker line-up is available online at

ACNR 2015;16(2):29. Published online 14/6/16